Amylyx Pharmaceuticals, Inc.

AMLXNASDAQHealthcare● Active

$12.87

$-0.45(-3.38%)

Market Cap$1.1B

P/E Ratio—

52W High$18.605

52W Low$4.76

Avg Volume1.1M

Open$13.51

Beta-0.16

Insider Trades Ownership Employees

Amylyx Pharmaceuticals, Inc. (AMLX) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · AMLX · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.04

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 4%Active transactions only · RSU vesting excluded96% Sell ↓

Amylyx Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

AMLX insider buying and selling by quarter

AMLX insider selling · AMLX insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

1.8M925K0

2024 Q2

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · AMLX ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

AMLX executive sell shares · AMLX board member insider trading · AMLX insider trading SEC filing

Showing 73 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 21, 2026	Firestone Karen Director	Purchase	3,800	$13.51	$51K	66,900	Form 4
Mar 5, 2026	Cohen Joshua B Co-Chief Executive Officer · Director	Award	248,865	—	—	3,583,548	Form 4
Mar 5, 2026	Mazzariello Gina Chief Legal Officer	Award	74,660	—	—	209,090	Form 4
Mar 5, 2026	FRATES JAMES M CFO	Award	95,990	—	—	261,628	Form 4
Mar 5, 2026	Klee Justin B. Co-Chief Executive Officer · Director	Award	248,865	—	—	3,583,481	Form 4
Mar 5, 2026	Bedrosian Camille L Chief Medical Officer	Award	95,990	—	—	265,285	Form 4
Mar 2, 2026	Klee Justin B. Co-Chief Executive Officer · Director	Sale	29,282	$14.47	$424K	3,334,616	Form 4
Mar 2, 2026	Cohen Joshua B Co-Chief Executive Officer · Director	Sale	29,282	$14.48	$424K	3,334,683	Form 4
Mar 2, 2026	Bedrosian Camille L Chief Medical Officer	Sale	6,461	$14.58	$94K	169,295	Form 4
Mar 2, 2026	FRATES JAMES M CFO	Sale	7,909	$14.52	$115K	165,638	Form 4
Mar 2, 2026	Mazzariello Gina Chief Legal Officer	Sale	6,844	$14.52	$99K	134,430	Form 4
Feb 23, 2026	Mazzariello Gina Chief Legal Officer	Sale	3,419	$14.14	$48K	141,274	Form 4
Feb 2, 2026	FRATES JAMES M CFO	Sale	3,557	$14.65	$52K	173,547	Form 4
Feb 2, 2026	Cohen Joshua B Co-Chief Executive Officer · Director	Sale	15,500	$14.68	$228K	3,363,965	Form 4
Feb 2, 2026	Mazzariello Gina Chief Legal Officer	Sale	3,448	$14.65	$51K	144,693	Form 4
Feb 2, 2026	Klee Justin B. Co-Chief Executive Officer · Director	Sale	15,500	$14.69	$228K	3,363,898	Form 4
Jan 15, 2026	Cohen Joshua B Co-Chief Executive Officer · Director	Option	197,182	$7.57	$1.49M⚡	3,514,814	Form 4
Jan 16, 2026	Cohen Joshua B Co-Chief Executive Officer · Director	Option	2,818	$7.57	$21K	3,381,439	Form 4
Jan 16, 2026	Cohen Joshua B Co-Chief Executive Officer · Director	Sale	1,974	$13.83	$27K	3,379,465	Form 4
Jan 15, 2026	Cohen Joshua B Co-Chief Executive Officer · Director	Sale	136,193	$13.59	$1.85M⚡	3,378,621	Form 4
Jan 15, 2026	Klee Justin B. Co-Chief Executive Officer · Director	Option	197,153	$7.57	$1.49M⚡	3,514,739	Form 4
Jan 16, 2026	Klee Justin B. Co-Chief Executive Officer · Director	Option	2,847	$7.57	$22K	3,381,393	Form 4
Jan 16, 2026	Klee Justin B. Co-Chief Executive Officer · Director	Sale	1,995	$13.89	$28K	3,379,398	Form 4
Jan 15, 2026	Klee Justin B. Co-Chief Executive Officer · Director	Sale	136,193	$13.58	$1.85M⚡	3,378,546	Form 4
Jan 12, 2026	MILNE GEORGE M JR Director	Gift	17,780	—	—	812,881	Form 4

Firestone Karen

Director

Purchase

Date

May 21

3,800

Price

$13.51

Value

$51K

View Form 4 on SEC.gov

Cohen Joshua B

Co-Chief Executive Officer · Director

Award

Date

Mar 5

248,865

Price

—

Value

—

View Form 4 on SEC.gov

Mazzariello Gina

Chief Legal Officer

Award

Date

Mar 5

74,660

Price

—

Value

—

View Form 4 on SEC.gov

FRATES JAMES M

CFO

Award

Date

Mar 5

95,990

Price

—

Value

—

View Form 4 on SEC.gov

Klee Justin B.

Co-Chief Executive Officer · Director

Award

Date

Mar 5

248,865

Price

—

Value

—

View Form 4 on SEC.gov

Bedrosian Camille L

Chief Medical Officer

Award

Date

Mar 5

95,990

Price

—

Value

—

View Form 4 on SEC.gov

Klee Justin B.

Co-Chief Executive Officer · Director

Sale

Date

Mar 2

29,282

Price

$14.47

Value

$424K

View Form 4 on SEC.gov

Cohen Joshua B

Co-Chief Executive Officer · Director

Sale

Date

Mar 2

29,282

Price

$14.48

Value

$424K

View Form 4 on SEC.gov

Bedrosian Camille L

Chief Medical Officer

Sale

Date

Mar 2

6,461

Price

$14.58

Value

$94K

View Form 4 on SEC.gov

FRATES JAMES M

CFO

Sale

Date

Mar 2

7,909

Price

$14.52

Value

$115K

View Form 4 on SEC.gov

Mazzariello Gina

Chief Legal Officer

Sale

Date

Mar 2

6,844

Price

$14.52

Value

$99K

View Form 4 on SEC.gov

Mazzariello Gina

Chief Legal Officer

Sale

Date

Feb 23

3,419

Price

$14.14

Value

$48K

View Form 4 on SEC.gov

FRATES JAMES M

CFO

Sale

Date

Feb 2

3,557

Price

$14.65

Value

$52K

View Form 4 on SEC.gov

Cohen Joshua B

Co-Chief Executive Officer · Director

Sale

Date

Feb 2

15,500

Price

$14.68

Value

$228K

View Form 4 on SEC.gov

Mazzariello Gina

Chief Legal Officer

Sale

Date

Feb 2

3,448

Price

$14.65

Value

$51K

View Form 4 on SEC.gov

Klee Justin B.

Co-Chief Executive Officer · Director

Sale

Date

Feb 2

15,500

Price

$14.69

Value

$228K

View Form 4 on SEC.gov

Cohen Joshua B

Co-Chief Executive Officer · Director

Option

Date

Jan 15

197,182

Price

$7.57

Value

$1.49M ⚡

View Form 4 on SEC.gov

Cohen Joshua B

Co-Chief Executive Officer · Director

Option

Date

Jan 16

2,818

Price

$7.57

Value

$21K

View Form 4 on SEC.gov

Cohen Joshua B

Co-Chief Executive Officer · Director

Sale

Date

Jan 16

1,974

Price

$13.83

Value

$27K

View Form 4 on SEC.gov

Cohen Joshua B

Co-Chief Executive Officer · Director

Sale

Date

Jan 15

136,193

Price

$13.59

Value

$1.85M ⚡

View Form 4 on SEC.gov

Klee Justin B.

Co-Chief Executive Officer · Director

Option

Date

Jan 15

197,153

Price

$7.57

Value

$1.49M ⚡

View Form 4 on SEC.gov

Klee Justin B.

Co-Chief Executive Officer · Director

Option

Date

Jan 16

2,847

Price

$7.57

Value

$22K

View Form 4 on SEC.gov

Klee Justin B.

Co-Chief Executive Officer · Director

Sale

Date

Jan 16

1,995

Price

$13.89

Value

$28K

View Form 4 on SEC.gov

Klee Justin B.

Co-Chief Executive Officer · Director

Sale

Date

Jan 15

136,193

Price

$13.58

Value

$1.85M ⚡

View Form 4 on SEC.gov

MILNE GEORGE M JR

Director

Gift

Date

Jan 12

17,780

Price

—

Value

—

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About AMLX insider trading

AMLX insider trades

Amylyx Pharmaceuticals, Inc. (AMLX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Cohen Joshua B (Co-Chief Executive Officer · Director), Klee Justin B. (Co-Chief Executive Officer · Director), Mazzariello Gina (Chief Legal Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. AMLX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Amylyx Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

AMLX insider trading · 5 questions

The insiders of Amylyx Pharmaceuticals, Inc. (AMLX) include executives and directors such as Cohen Joshua B (Co-Chief Executive Officer · Director), Klee Justin B. (Co-Chief Executive Officer · Director), Mazzariello Gina (Chief Legal Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

AMLX board member insider tradingwho are AMLX insidersAMLX insider rosterAmylyx Pharmaceuticals, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026